Ironwood Pharmaceuticals Company Profile (NASDAQ:IRWD)

About Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals logoIronwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IRWD
  • CUSIP: 46333X10
  • Web:
  • Market Cap: $2.31417 billion
  • Outstanding Shares: 149,591,000
Average Prices:
  • 50 Day Moving Avg: $15.92
  • 200 Day Moving Avg: $16.86
  • 52 Week Range: $12.48 - $19.94
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -29.06
  • P/E Growth: -0.26
Sales & Book Value:
  • Annual Revenue: $270.81 million
  • Price / Sales: 8.51
  • Book Value: $0.03 per share
  • Price / Book: 513.33
  • EBITDA: ($84,770,000.00)
  • Net Margins: -52.97%
  • Return on Equity: -333.83%
  • Return on Assets: -18.83%
  • Debt-to-Equity Ratio: 79.64%
  • Current Ratio: 4.27%
  • Quick Ratio: 4.27%
  • Average Volume: 1.24 million shs.
  • Beta: 1.48
  • Short Ratio: 11.15

Frequently Asked Questions for Ironwood Pharmaceuticals (NASDAQ:IRWD)

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.05. The firm earned $65.10 million during the quarter, compared to analysts' expectations of $70 million. Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. The company's revenue for the quarter was up 19.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.16) EPS. View Ironwood Pharmaceuticals' Earnings History.

When will Ironwood Pharmaceuticals make its next earnings announcement?

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Ironwood Pharmaceuticals.

Where is Ironwood Pharmaceuticals' stock going? Where will Ironwood Pharmaceuticals' stock price be in 2017?

8 analysts have issued 1 year price targets for Ironwood Pharmaceuticals' shares. Their predictions range from $13.00 to $21.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $18.29 in the next twelve months. View Analyst Ratings for Ironwood Pharmaceuticals.

Who are some of Ironwood Pharmaceuticals' key competitors?

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the folowing people:

  • Peter M. Hecht Ph.D., Chief Executive Officer, Director
  • Thomas Graney, Chief Financial Officer, Senior Vice President - Finance, Corporate Strategy
  • Mark G. Currie Ph.D., Senior Vice President, Chief Scientific Officer, President - Research and Development
  • Thomas A. McCourt, Senior Vice President - Marketing and Sales, Chief Commercial Officer
  • Halley E. Gilbert Esq., Senior Vice President, Chief Legal Officer, Secretary
  • Christopher I. Wright M.D. Ph.D., Senior Vice President - Global Development and Chief Development Officer
  • Terrance G. McGuire, Non-Executive Independent Chairman of the Board
  • Andrew Dreyfus, Independent Director
  • Marsha H. Fanucci, Independent Director
  • Julie H. McHugh, Independent Director

How do I buy Ironwood Pharmaceuticals stock?

Shares of Ironwood Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of Ironwood Pharmaceuticals stock can currently be purchased for approximately $15.40.

MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  249 (Vote Outperform)
Underperform Votes:  328 (Vote Underperform)
Total Votes:  577
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ironwood Pharmaceuticals (NASDAQ:IRWD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $18.29 (18.74% upside)
Consensus Price Target History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Price Target History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Analysts' Ratings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/25/2017MizuhoReiterated RatingBuy$23.00 -> $20.00MediumView Rating Details
8/21/2017Cowen and CompanySet Price TargetBuy$20.00MediumView Rating Details
7/22/2017Wells Fargo & CompanySet Price TargetBuy$19.00LowView Rating Details
7/21/2017Wood & CompanyDowngradeOverweight -> NeutralLowView Rating Details
7/21/2017J P Morgan Chase & CoReiterated RatingOverweight -> Neutral$20.00 -> $19.00HighView Rating Details
6/16/2017WedbushReiterated RatingNeutral$13.00LowView Rating Details
3/13/2017BTIG ResearchReiterated RatingBuy$18.00 -> $21.00LowView Rating Details
2/22/2017Barclays PLCReiterated RatingEqual Weight -> Equal Weight$13.00 -> $16.00N/AView Rating Details
9/27/2016WallachBeth CapitalBoost Price TargetHold$15.00 -> $17.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingMarket Perform$10.00 -> $14.00N/AView Rating Details
4/28/2016JP Morgan CazenoveReiterated RatingOverweight$15.00N/AView Rating Details
4/26/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
3/21/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$14.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Earnings by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Earnings History by Quarter for Ironwood Pharmaceuticals (NASDAQ IRWD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017N/AView Earnings Details
8/3/2017Q2 2017($0.23)($0.28)$70.00 million$65.10 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.19)($0.33)$69.39 million$52.16 millionViewListenView Earnings Details
2/21/2017Q416($0.24)($0.12)$77.34 million$87.50 millionViewListenView Earnings Details
11/3/2016Q316($0.23)($0.18)$60.01 million$66.00 millionViewN/AView Earnings Details
8/4/2016Q216($0.15)($0.16)$54.49 million$54.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.14)($0.08)$52.97 million$66.00 millionViewN/AView Earnings Details
2/18/2016Q415($0.17)($0.10)$44.78 million$53.30 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.25)$39.81 million$39.60 millionViewListenView Earnings Details
8/5/2015Q215($0.22)($0.34)$36.08 million$27.74 millionViewN/AView Earnings Details
5/5/2015Q115($0.23)($0.24)$32.30 million$28.90 millionViewN/AView Earnings Details
2/12/2015Q414($0.21)($0.27)$35.20 million$38.10 millionViewListenView Earnings Details
11/4/2014Q314($0.32)($0.30)$21.20 million$16.90 millionViewListenView Earnings Details
8/4/2014Q214($0.36)($0.38)$15.75 million$6.84 millionViewListenView Earnings Details
4/29/2014Q1($0.45)($0.38)$8.52 million$14.60 millionViewListenView Earnings Details
1/21/2014Q413($0.50)($0.43)$7.13 million$5.00 millionViewListenView Earnings Details
10/22/2013Q313($0.57)($0.51)$6.54 million$4.90 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.70)($0.57)$6.32 million$9.70 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.71)($0.87)$8.94 million$3.30 millionViewN/AView Earnings Details
1/15/2013Q4 2012($0.49)($0.41)$16.17 million$27.00 millionViewN/AView Earnings Details
10/16/2012$0.17$0.42ViewN/AView Earnings Details
7/17/2012($0.31)($0.38)ViewN/AView Earnings Details
5/1/2012($0.23)($0.34)ViewN/AView Earnings Details
2/28/2012($0.11)($0.07)ViewN/AView Earnings Details
11/7/2011($0.20)($0.21)ViewN/AView Earnings Details
8/11/2011($0.18)($0.19)ViewN/AView Earnings Details
5/12/2011($0.17)($0.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)
2017 EPS Consensus Estimate: ($0.75)
2018 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.24)($0.20)($0.22)
Q2 20172($0.23)($0.21)($0.22)
Q3 20172($0.21)($0.12)($0.17)
Q4 20172($0.19)($0.10)($0.15)
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)


Dividend History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Insider Ownership Percentage: 7.63%
Institutional Ownership Percentage: 97.16%
Insider Trades by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Insider Trades by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017Julie MchughDirectorSell1,500$16.16$24,240.00View SEC Filing  
8/18/2017Gina ConsylmanInsiderSell207$14.34$2,968.38View SEC Filing  
6/22/2017Halley E GilbertInsiderSell35,000$19.75$691,250.00View SEC Filing  
5/15/2017Thomas A MccourtInsiderSell30,000$18.20$546,000.00View SEC Filing  
2/14/2017Halley E GilbertInsiderSell37,385$16.75$626,198.75View SEC Filing  
1/12/2017Peter M HechtCEOSell65,987$15.67$1,034,016.29View SEC Filing  
12/5/2016Lawrence S OlanoffDirectorSell3,200$15.68$50,176.00View SEC Filing  
9/6/2016Lawrence S OlanoffDirectorSell3,200$13.72$43,904.00View SEC Filing  
8/19/2016Gina ConsylmanInsiderSell207$13.54$2,802.78View SEC Filing  
6/3/2016Lawrence S OlanoffDirectorSell2,200$12.92$28,424.00View SEC Filing  
5/25/2016Halley E GilbertInsiderSell20,275$12.19$247,152.25View SEC Filing  
3/11/2016Peter M HechtCEOSell120,000$10.72$1,286,400.00View SEC Filing  
3/7/2016Lawrence S OlanoffDirectorSell2,200$11.11$24,442.00View SEC Filing  
2/24/2016Edward P OwensDirectorBuy10,000$8.32$83,200.00View SEC Filing  
2/24/2016Gina ConsylmanCAOSell420$8.50$3,570.00View SEC Filing  
2/24/2016Mark G CurrieInsiderSell152,154$8.53$1,297,873.62View SEC Filing  
2/24/2016Thomas GraneyCFOSell563$8.50$4,785.50View SEC Filing  
12/15/2015Peter M. HechtCEOSell73,418$11.07$812,737.26View SEC Filing  
12/7/2015Lawrence S OlanoffDirectorSell2,200$11.77$25,894.00View SEC Filing  
9/4/2015Lawrence S OlanoffDirectorSell3,725$10.97$40,863.25View SEC Filing  
3/17/2015Peter M HechtCEOSell200,000$15.62$3,124,000.00View SEC Filing  
3/12/2015Joseph C Cook JrDirectorSell5,883$15.54$91,421.82View SEC Filing  
3/10/2015Bryan E RobertsDirectorSell95,998$15.20$1,459,169.60View SEC Filing  
3/3/2015Peter M HechtCEOSell63,442$15.75$999,211.50View SEC Filing  
2/20/2015Joseph C Cook JrDirectorSell35,500$15.60$553,800.00View SEC Filing  
12/15/2014Bryan E RobertsDirectorSell19,792$15.20$300,838.40View SEC Filing  
6/12/2014Bryan E RobertsDirectorSell200,000$14.24$2,848,000.00View SEC Filing  
5/29/2014Michael J HigginsCOOSell50,000$14.56$728,000.00View SEC Filing  
5/22/2014Mark CurrieInsiderSell25,000$13.93$348,250.00View SEC Filing  
4/24/2014Mark CurrieInsiderSell25,000$11.67$291,750.00View SEC Filing  
1/23/2014Mark CurrieInsiderSell20,000$14.38$287,600.00View SEC Filing  
1/14/2014Bryan RobertsDirectorSell21,200$12.57$266,484.00View SEC Filing  
1/13/2014Bryan RobertsDirectorSell823,350$12.71$10,464,778.50View SEC Filing  
1/6/2014Bryan RobertsDirectorSell55,450$12.01$665,954.50View SEC Filing  
11/7/2013Terrance McguireDirectorSell2,083$9.11$18,976.13View SEC Filing  
6/17/2013Michael J HigginsCOOSell150,000$11.74$1,761,000.00View SEC Filing  
3/11/2013Thomas A MccourtInsiderSell40,000$17.00$680,000.00View SEC Filing  
11/5/2012Peter M HechtCEOBuy50,000$11.65$582,500.00View SEC Filing  
10/8/2012Fmr LlcInsiderSell19,305$13.02$251,351.10View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Latest Headlines for Ironwood Pharmaceuticals (NASDAQ:IRWD)
DateHeadline logoIronwood Pharmaceuticals Presenting Linaclotide Data at the World Congress of Gastroenterology at ACG 2017 - October 16 at 7:29 PM logoETFs with exposure to Ironwood Pharmaceuticals, Inc. : October 16, 2017 - October 16 at 7:29 PM logoIronwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : October 16, 2017 - October 16 at 7:29 PM logoIronwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : October 13, 2017 - October 13 at 7:50 PM logo Analysts Anticipate Ironwood Pharmaceuticals, Inc. (IRWD) Will Announce Quarterly Sales of $68.04 Million - October 13 at 5:52 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Receives Average Recommendation of "Hold" from Brokerages - October 7 at 7:36 AM logoIRWD Makes Bullish Cross Above Critical Moving Average - October 7 at 5:00 AM logoETFs with exposure to Ironwood Pharmaceuticals, Inc. : October 3, 2017 - October 5 at 6:43 AM logoIronwood Pharmaceuticals Struggles With Slump In Sales, Net Losses - September 26 at 5:04 PM logoIronwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : September 26, 2017 - September 26 at 10:19 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Expected to Announce Quarterly Sales of $68.04 Million - September 24 at 1:48 AM logo-$0.23 EPS Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter - September 22 at 6:22 PM logoETFs with exposure to Ironwood Pharmaceuticals, Inc. : September 13, 2017 - September 14 at 6:33 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Given Average Recommendation of "Hold" by Brokerages - September 12 at 6:56 AM logoTiGenix strengthens US operations with senior appointments - September 12 at 1:34 AM logoIronwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 - September 11 at 8:42 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Director Sells $24,240.00 in Stock - September 7 at 8:28 PM logoForm 8-K IRONWOOD PHARMACEUTICALS For: Sep 01 - September 6 at 7:58 PM logoIronwood Pharmaceuticals Announces Leadership Change - September 6 at 7:58 PM logoContrasting Merrimack Pharmaceuticals (MACK) and Ironwood Pharmaceuticals (IRWD) - September 5 at 6:16 AM logo$68.04 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter - September 5 at 3:00 AM logoWhy Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report? - September 4 at 6:52 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Expected to Post Earnings of -$0.23 Per Share - September 4 at 12:20 AM logoIronwood Pharmaceuticals to Present at Upcoming September Investor Conferences - August 31 at 8:00 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Stock Rating Reaffirmed by Mizuho - August 26 at 8:32 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Short Interest Up 16.0% in August - August 26 at 1:20 AM logoInteresting IRWD Put And Call Options For October 20th - August 24 at 8:04 AM logoToday's Research Reports on Stocks to Watch: Medtronic and Ironwood Pharmaceuticals - August 24 at 8:04 AM logoIronwood Pharma's Combination Gout Drug Gets FDA Approval - August 23 at 5:57 AM logoIronwood Pharma's Combination Gout Drug Gets FDA Approval - August 23 at 5:57 AM logoFDA approves Ironwood Pharma's gout drug - August 21 at 7:09 PM logoIronwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers - August 21 at 7:09 PM logoIronwood Pharma Muted Despite FDA Approval - August 21 at 7:09 PM logoIronwood gets FDA approval for new drug for gout - August 21 at 7:09 PM logoCowen and Company Analysts Give Ironwood Pharmaceuticals, Inc. (IRWD) a $20.00 Price Target - August 21 at 6:02 PM logoGeneric Drugs Stock Performance Review -- Patheon, Zoetis, Ironwood Pharma, and Medicines Co. - August 21 at 8:52 AM logoIronwood Pharma (IRWD) Announces FDA Approval of DUZALLO for Treatment of Hyperuricemia in Patients with Uncontrolled Gout - August 21 at 8:52 AM logoIronwood Pharmaceuticals Announces FDA Approval of DUZALLO® (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout - August 21 at 8:52 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Recommendation of "Hold" from Analysts - August 18 at 6:40 AM logoSee what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. - August 12 at 12:21 AM logoFY2021 EPS Estimates for Ironwood Pharmaceuticals, Inc. Reduced by Analyst (IRWD) - August 7 at 10:22 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Given a $20.00 Price Target by Cowen and Company Analysts - August 5 at 9:56 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - August 5 at 8:22 PM logoEdited Transcript of IRWD earnings conference call or presentation 3-Aug-17 8:30pm GMT - August 4 at 8:13 PM logoETFs with exposure to Ironwood Pharmaceuticals, Inc. : August 4, 2017 - August 4 at 1:08 AM logoIronwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : August 4, 2017 - August 4 at 1:08 AM logoIronwood Pharmaceuticals Provides Second Quarter 2017 Investor Update - August 3 at 8:08 PM logoIronwood reports 2Q loss - August 3 at 8:08 PM logoMizuho Reiterates Buy Rating for Ironwood Pharmaceuticals, Inc. (IRWD) - August 2 at 8:22 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Rating of "Hold" from Analysts - July 24 at 9:18 AM



Ironwood Pharmaceuticals (IRWD) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.